The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
Hagen Schwenzer(University of Oxford), Sarah P. Blagden(Churchill Hospital), Sebastian Nijman(Austrian Academy of Sciences), Ruth Plummer(National Health Service), Mustafa Elshani(University of St Andrews), Gareth L. Bond(Ludwig Cancer Research), Mary Kudsy(University of St Andrews), Stefan N. Symeonides(Edinburgh Cancer Research), Ruud van Stiphout(Nuffield Orthopaedic Centre), Erica De Zan(Nuffield Orthopaedic Centre), David J. Harrison(NHS Lothian), Alistair Easton(Manchester Academic Health Science Centre), Farasat Kazmi(University of Oxford), Josephine Morris(University of Oxford), Valentina Ferrari(Cardiff University), James Chettle(University of Oxford), Michaela Serpi(Cardiff University), Leticia Campo(University of Oxford), In Hwa Um(University of St Andrews)
Cited by 44
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406